Cargando…
Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis
BACKGROUND: Pimavanserin is approved for treatment of Parkinson disease (PD)-related psychosis, but its use has been associated with an increased risk of death during clinical trials, as well as during postmarketing surveillance. Previous reports on the association between pimavanserin and mortality...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391001/ https://www.ncbi.nlm.nih.gov/pubmed/34057395 http://dx.doi.org/10.18553/jmcp.2021.27.6.785 |